Open-Label Surufatinib in European Patients With NET

Stopped early · Phase 2

Conditions studied: Neuroendocrine Tumours, Neuroendocrine Tumour of the Lung, Small Intestinal NET

In brief

This is a Phase 2, open-label, multi-centre study of surufatinib in patients with low to intermediate grade (Grade 1 or Grade 2), well-differentiated neuroendocrine tumours (NETs).

Key facts

Study ID
NCT04579679
Run by
Hutchmed
People needed
78
Starts
2021-08-13
Expected to finish
2024-10-15
Last updated by the study team
2025-07-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.